

关于市售含戊糖片球菌 CECT8330 和长双歧杆菌长亚种 CECT7894 益生菌产品的抽查声明
Inspection statement on probiotic products containing *Pediococcus pentosaceus* CECT8330 and *Bifidobacterium longum* subsp. *longum* CECT7894

AB-BIOTICS S.A. 是一家专注于创新微生物产品研发和商业化的益生菌企业，在益生菌领域拥有深厚的技术积累。

AB-BIOTICS S.A. is a probiotic enterprise specializing in the research, development, and commercialization of innovative microbial products, with profound technical expertise in the probiotic field.

截至目前，AB-BIOTICS S.A. 已获得超 200 项国际专利授权，专利范围涵盖多种益生菌菌株及其在不同健康领域的应用，其中包含戊糖片球菌 CECT8330 和长双歧杆菌长亚种 CECT7894 的菌株组合 AB-Kolicare®，临床有效剂量为 4×10^9 CFU/ml（或 1×10^9 CFU/0.25ml）。

To date, AB-BIOTICS S.A. has obtained over 200 international patent authorizations, covering various probiotic strains and their applications in different health fields, including the strain combination AB-Kolicare® of *Pediococcus pentosaceus* CECT8330 and *Bifidobacterium longum* subsp. *longum* CECT7894, clinical dose: 4×10^9 CFU/ml (or 1×10^9 CFU/0.25ml).

AB-BIOTICS S.A. 作为 AB-Kolicare® 菌株组合专利的持有方（专利号：ZL201480050859.1），于 2025 年 4 月从市场采购了直接宣称或暗示含有该菌株的益生菌油滴剂产品。这些产品均不由 AB-BIOTICS S.A. 公司生产，也未经 AB-BIOTICS S.A. 公司备案授权销售。检测采用常规聚合酶链式反应（PCR）、定量聚合酶链式反应（qPCR）等分析方法进行了抽样检测分析。以下为本次抽查中不良产品结果：

As the patent holder of AB-Kolicare® strains (Patent No.: ZL201480050859.1), in April 2025 AB-BIOTICS S.A. purchased probiotic oil drop products from the Chinese market, directly claiming or implying the presence of these strains. These products are not produced by AB-BIOTICS S.A. nor are authorized for sale by AB-BIOTICS S.A. Sampling analysis was conducted using analytical methods including conventional polymerase chain reaction (PCR) and quantitative polymerase chain reaction (qPCR) etc. The following are results of the defective products from this random inspection:

1. D-Sorb - Vitality NutraHealth™


检测批次 Tested Lots: DA04241001-231, DA11241003-232, DA11241003-261, DA11241003-272



- CECT8330: 活菌计数为 4.78×10^8 - 1.30×10^9 CFU/ml，低于临床有效剂量。
CECT8330: viable counts 4.78×10^8 - 1.30×10^9 CFU/ml, lower than clinical effective dose.
- CECT7894: 活菌计数为 5.28×10^8 - 1.22×10^9 CFU/ml，低于临床有效剂量。
CECT7894: viable counts 5.28×10^8 - 1.22×10^9 CFU/ml, lower than the clinical effective dose.

2. PROBOLICS 90000 - Wangpu Le Yishun®

检测批次 Tested Lots: WP07232103-284, WP02242105-291, WP02242105-271



CECT8330: 活菌计数为 3.48×10^8 - 7.40×10^8 CFU/ml 远低于临床有效剂量。
CECT8330: viable counts 3.48×10^8 - 7.40×10^8 CFU/ml, lower than the clinical effective dose.

CECT7894: 活菌计数为 2.80×10^8 - 5.41×10^8 CFU/ml 远低于临床有效剂量。
CECT7894: viable counts 2.80×10^8 - 5.41×10^8 CFU/ml, lower than the clinical effective dose.

3. Kings HealthBay

检测批次 Tested Lots: 240208011-I04, 240208011-I04', 240208011-I52



CECT8330: 未检测到目标菌株。尽管该产品暗示宣称仅含此菌株，但 qPCR 及常规 PCR 均未验证其存在，仅观察到非目标革兰氏阳性球菌。

CECT8330: Target strain not detected. Despite the product's implied claim of containing only this strain, neither qPCR nor conventional PCR verified its presence, with only non-target Gram-positive cocci observed.

本次抽查结果显示，部分非 AB-BIOTICS S.A. 公司生产或非 AB-BIOTICS S.A. 公司授权销售的产品存在活菌计数不达临床有效剂量或未真实使用专利菌株的情况。AB-BIOTICS S.A. 高度重视消费者权益及市场合规性。我们在此严正提醒相关企业，需严格遵守专利授权规则及产品生产、标识规范。

The results of this random inspection show that some products that were not produced nor authorized for sale by AB-BIOTICS S.A. have deficiencies such as insufficient viable counts or untruthful use of patented strains. AB-BIOTICS S.A. attaches great importance to consumer rights and market compliance. We hereby solemnly remind all manufacturers to strictly comply with patent licensing rules, as well as product production and labeling standards.

为确保消费者获得真实、有效的产品，AB-BIOTICS S.A. 公司将继续对更多市售产品进行随机检测，并及时公布检测结果，以维护市场秩序和公共卫生权力。

To ensure that consumers receive genuine and effective products, AB-BIOTICS S.A. will continue to conduct random inspections on more commercially available products and promptly announce the test results to maintain market order and public health rights.



AB-BIOTICS

CHF: A-63497473

AB-BIOTICS S.A.

声明日期: 2025 年 7 月 7 日

AB-BIOTICS S.A.

Date of Statement: July 7, 2025